2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Writing Committee Members

doi:10.1161/CIR.0000000000001423

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Writing Committee Members

Research output: Contribution to journal › Review article › peer-review

162 Citations (Scopus)

Abstract

AIM – The “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.” METHODS – A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE – The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).

Original language	English (US)
Journal	Circulation
DOIs	https://doi.org/10.1161/CIR.0000000000001423
Publication status	Published - 2026
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

AHA Scientific Statements
HDL
LDL
anticholesteremic agents
atherosclerosis
atherosclerotic disease
cardiovascular disease
cardiovascular diseases
cholesterol
drug interactions
dyslipidemia(s)
hydroxymethylglutaryl-CoA reductase inhibitors
hypercholesterolemia
hyperlipid(a)emia/s
hyperlipoproteinemia type II
hypertriglyceridemia
hypolipidemic agents
lipids
lipoprotein(a)
primary prevention
risk Adjustment
risk assessment
risk factors
simvastatin
statin(s)
triglycerides

Access to Document

10.1161/CIR.0000000000001423

Fingerprint

Dive into the research topics of '2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines'. Together they form a unique fingerprint.

Cite this

@article{33d526a4ee514af080d4b47335d80673,

title = "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines",

abstract = "AIM {\textendash} The {\textquotedblleft}2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia{\textquotedblright} retires and replaces the {\textquotedblleft}2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.{\textquotedblright} METHODS {\textendash} A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE {\textendash} The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).",

keywords = "AHA Scientific Statements, HDL, LDL, anticholesteremic agents, atherosclerosis, atherosclerotic disease, cardiovascular disease, cardiovascular diseases, cholesterol, drug interactions, dyslipidemia(s), hydroxymethylglutaryl-CoA reductase inhibitors, hypercholesterolemia, hyperlipid(a)emia/s, hyperlipoproteinemia type II, hypertriglyceridemia, hypolipidemic agents, lipids, lipoprotein(a), primary prevention, risk Adjustment, risk assessment, risk factors, simvastatin, statin(s), triglycerides",

author = "\{Writing Committee Members\} and Mario Gaudino and Johnson, \{Heather M.\} and Anderson, \{Timothy S.\} and Bittner, \{Vera A.\} and Leslie Cho and Gradney, \{Kristen F.\} and Ijeoma Isiadinso and Marrs, \{Joel C.\} and Mulugeta, \{Wudeneh M.\} and Saseen, \{Joseph J.\} and Shapiro, \{Michael D.\} and Soffer, \{Daniel E.\} and Tynes, \{Sheila A.\} and Villavaso, \{Chlo{\'e} D.\} and Virani, \{Salim S.\}",

note = "Publisher Copyright: {\textcopyright} 2026 by the American College of Cardiology Foundation and the American Heart Association, Inc.",

year = "2026",

doi = "10.1161/CIR.0000000000001423",

language = "English (US)",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia

T2 - A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

AU - Writing Committee Members

AU - Gaudino, Mario

AU - Johnson, Heather M.

AU - Anderson, Timothy S.

AU - Bittner, Vera A.

AU - Cho, Leslie

AU - Gradney, Kristen F.

AU - Isiadinso, Ijeoma

AU - Marrs, Joel C.

AU - Mulugeta, Wudeneh M.

AU - Saseen, Joseph J.

AU - Shapiro, Michael D.

AU - Soffer, Daniel E.

AU - Tynes, Sheila A.

AU - Villavaso, Chloé D.

AU - Virani, Salim S.

PY - 2026

Y1 - 2026

N2 - AIM – The “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.” METHODS – A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE – The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).

AB - AIM – The “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.” METHODS – A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE – The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).

KW - AHA Scientific Statements

KW - HDL

KW - LDL

KW - anticholesteremic agents

KW - atherosclerosis

KW - atherosclerotic disease

KW - cardiovascular disease

KW - cardiovascular diseases

KW - cholesterol

KW - drug interactions

KW - dyslipidemia(s)

KW - hydroxymethylglutaryl-CoA reductase inhibitors

KW - hypercholesterolemia

KW - hyperlipid(a)emia/s

KW - hyperlipoproteinemia type II

KW - hypertriglyceridemia

KW - hypolipidemic agents

KW - lipids

KW - lipoprotein(a)

KW - primary prevention

KW - risk Adjustment

KW - risk assessment

KW - risk factors

KW - simvastatin

KW - statin(s)

KW - triglycerides

UR - https://www.scopus.com/pages/publications/105041712454

U2 - 10.1161/CIR.0000000000001423

DO - 10.1161/CIR.0000000000001423

M3 - Review article

C2 - 41824552

AN - SCOPUS:105041712454

SN - 0009-7322

JO - Circulation

JF - Circulation

ER -

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this